Blood Marker HSP47 in Adults with Clots, Heart Attack or Stroke
Studies whether HSP47 blood levels differ in adults with blood clots, heart attack or stroke.
Plain-language title generated from the registry record
Registry title: Heat Shock Protein 47 in Thrombosis
Key facts
- Where
- Aarhus, DenmarkSee the site
Where in Denmark
- Aarhus University HospitalAarhus, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT06731673
- Record updated
- 21 August 2025
- Original description
The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are:Read full original descriptionShow less
Heat Shock Protein 47: A Novel Biomarker of Thrombosis Risk
The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are:
1. Are platelet levels of HSP47 higher in patients with acute VTE, AMI or stroke, compared to healthy volunteers. 2. Does platelet levels of HSP47 remain elevated in patients with acute thrombotic events compared to healthy volunteers at 3 and 12-months of follow-up. 3. Are platelet levels of HSP47 postively associated with platelet function and negatively associated with fibrinolytic capacity in patients with an acute thrombotic event.
Participants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up. Healthy volunteers will be giving a blood sample once.
Inclusion: 18 years of age or older; Informed consent; VTE group:; Deep vein thrombosis confirmed on ultrasonography OR; Pulmonary embolism confirmed on computed tomography angiography (CTA); AMI group:; ST-segment elevation on electrocardiogram (ECG) AND; Culprit lesion(s) on coronary angiography; Stroke group:; Stroke confirmed on magnetic resonance imaging AND; Atrial fibrillation (Detected on ECG, telemtry or Holter monitoring) AND; Stroke localisation classic for AFib: cortical, cerebellar, brainstem or subcortical >1.5 cm in diameter; Healthy group:; Healthy.
Exclusion: Prior VTE, AMI, stroke or other thromboembolic event; Known haematological disorders; Active haematological malignancy; Takotsubo cardiomyopathy; Stroke; Stroke from other causes, e.g. findings pointing towards large vessel disease; Healthy; Known acute or chronic disease; Severe renal insufficiency defined as eGFR <15 or dialysis; VTE - Pulmonary embolism incidentally detected by CTA conducted for purposes unrelated to pulmonary embolism assessment without concomitant DVT; AMI; <18 years of age; no informed consent; Coronary dissection.